BR112023002617A2 - Compostos, composições e métodos - Google Patents

Compostos, composições e métodos

Info

Publication number
BR112023002617A2
BR112023002617A2 BR112023002617A BR112023002617A BR112023002617A2 BR 112023002617 A2 BR112023002617 A2 BR 112023002617A2 BR 112023002617 A BR112023002617 A BR 112023002617A BR 112023002617 A BR112023002617 A BR 112023002617A BR 112023002617 A2 BR112023002617 A2 BR 112023002617A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
compounds
nlrp3
stereoisomer
Prior art date
Application number
BR112023002617A
Other languages
English (en)
Inventor
A Ii Craig Robert
De Vicente Fidalgo Javier
A Estrada Anthony
M Fox Brian
Hu Cheng
W Lexa Katrina
G Nilewski Lizanne
Osipov Maksim
Thottumkara Arun
L Bagdasarian Alex
J Huffman Benjamin
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of BR112023002617A2 publication Critical patent/BR112023002617A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTOS, COMPOSIÇÕES E MÉTODOS. A presente invenção refere-se geralmente a moduladores de molécula pequena do Domínio da Família NLR Contendo 3 (NLRP3), ou um sal farmaceuticamente aceitável, análogo isotopicamente enriquecido, estereoisômero, mistura de estereoisômeros, ou pró-fármaco dos mesmos, métodos de produção e intermediários dos mesmos, e métodos de uso dos mesmos.
BR112023002617A 2020-08-14 2021-08-13 Compostos, composições e métodos BR112023002617A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063066074P 2020-08-14 2020-08-14
US202163151600P 2021-02-19 2021-02-19
PCT/US2021/045924 WO2022036204A1 (en) 2020-08-14 2021-08-13 Compounds, compositions and methods

Publications (1)

Publication Number Publication Date
BR112023002617A2 true BR112023002617A2 (pt) 2023-05-09

Family

ID=80246652

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002617A BR112023002617A2 (pt) 2020-08-14 2021-08-13 Compostos, composições e métodos

Country Status (12)

Country Link
US (1) US20230357162A1 (pt)
EP (1) EP4196125A1 (pt)
JP (1) JP2023538304A (pt)
KR (1) KR20230051528A (pt)
CN (1) CN116261456A (pt)
AU (1) AU2021324901A1 (pt)
BR (1) BR112023002617A2 (pt)
CA (1) CA3190495A1 (pt)
IL (1) IL300289A (pt)
MX (1) MX2023001757A (pt)
TW (1) TW202220963A (pt)
WO (1) WO2022036204A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022301461A1 (en) 2021-07-01 2024-02-15 Janssen Pharmaceutica Nv 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
WO2023158708A1 (en) * 2022-02-16 2023-08-24 Denali Therapeutics Inc. Compounds, compositions, and methods
TW202402747A (zh) * 2022-03-30 2024-01-16 美商戴納立製藥公司 化合物、組合物及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012129057A2 (en) * 2011-03-18 2012-09-27 The Regents Of The University Of California Ssh-2 (slingshot-2) inhibitors and methods for making and using them
MX2014007969A (es) * 2011-12-29 2015-02-10 Pharmacyclics Inc Hidroxiamidas de ácido cinámico como inhibidores de la histona desacetilasa 8.
JP6545148B2 (ja) * 2013-03-13 2019-07-17 フラットリー ディスカバリー ラブ，エルエルシー ピリダジノン化合物及び嚢胞性線維症の治療のための方法
GB201710851D0 (en) * 2017-07-06 2017-08-23 Galápagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
EP3911416B1 (en) * 2019-01-14 2024-06-12 Innate Tumor Immunity, Inc. Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
JP2023527010A (ja) * 2020-05-28 2023-06-26 ヤンセン ファーマシューティカ エヌ．ベー． 化合物

Also Published As

Publication number Publication date
AU2021324901A1 (en) 2023-03-02
JP2023538304A (ja) 2023-09-07
CN116261456A (zh) 2023-06-13
EP4196125A1 (en) 2023-06-21
US20230357162A1 (en) 2023-11-09
WO2022036204A1 (en) 2022-02-17
IL300289A (en) 2023-04-01
TW202220963A (zh) 2022-06-01
CA3190495A1 (en) 2022-02-17
KR20230051528A (ko) 2023-04-18
MX2023001757A (es) 2023-02-22

Similar Documents

Publication Publication Date Title
BR112023002617A2 (pt) Compostos, composições e métodos
BR112022007867A2 (pt) Degradadores de pequena molécula de helios e métodos de uso
UY37617A (es) Moduladores de la proteína reguladora de la conductancia transmembrana en fibrosis quística y métodos de empleo
MX2023000001A (es) Compuestos, composiciones y metodos.
BR0308261A (pt) Métodos extrativos para puruficação de sucralose
AR048973A1 (es) (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas
BRPI0507830A (pt) derivados azabicìclicos, o respectivo processo de preparo e as composições farmacêuticas que os contêm
BR112022002520A2 (pt) Piperidinil-metil-purina-aminas como inibidores de nsd2 e agentes anticâncer
BR0206955A (pt) Ligantes de receptores de canabinóides
BRPI0817096A8 (pt) Análogo de tiazolidinodiona e composição farmacêutica que o compreende
BR112021020027A2 (pt) Compostos, composições e métodos
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
ME01595B (me) Benzamidinska jedinjenja koja su korisna kao inhibitori histonske deacetilaze
PE20211461A1 (es) Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona
AR064307A1 (es) Monofosfatos utiles para el tratamiento de la inflamacion pulmonar y broncoconstriccion, formulaciones aerosolicas que los contienen, y metodo de preparacion.
BR112023006761A2 (pt) Compostos de peptídeo curto de prolina modificado no anel, composição farmacêutica e uso dos mesmos
MX2021002529A (es) Analogos de illudin, usos de los mismos y metodos para sintetizar los mismos.
BR112021011325A2 (pt) Derivados de rapamicina
PE20211774A1 (es) Piridazinonas y sus metodos de uso
BR112022009209A2 (pt) Derivado de amida e método de preparação e uso do mesmo na medicina
PE20210343A1 (es) Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso
BR112021023927A2 (pt) Composto, e, composição farmacêutica
EA202092608A1 (ru) Спиропиперидиновые аллостерические модуляторы никотиновых ацетилхолиновых рецепторов
MX2023005906A (es) Compuestos, composiciones y metodos.
ECSP034494A (es) Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales